Benchmarking of a Multi-biomarker Low-volume Panel for Alzheimer’s Disease and Related Dementia Research

Tuesday, April 08, 2025 | 2pm EDT / 11am PDT

Featuring:

Laura Ibáñez, PhD

Assistant Professor of Psychiatry,
Washington University of Medicine

Carlos Cruchaga, PhD

Professor of Psychiatry,
Washington University of Medicine
Watch On Demand

Discover an informative webinar featuring leading researchers as they discuss advancements in biomarker discovery for Alzheimer’s disease (AD) and related dementias.

The expert speakers will present on the validation and application of a highly sensitive and low-volume multiplexed assay designed to detect key neurodegenerative disease biomarkers. They will explore how this platform enhances the measurement of critical Alzheimer’s biomarkers, such as pTau217, offering a minimally invasive and scalable approach for early diagnosis and disease monitoring in both sporadic and autosomal dominant AD.

They will follow with a discussion on large-scale plasma proteomics and its role in identifying disease-specific biomarkers across neurodegenerative diseases, including AD, Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD). Her research highlights the power of plasma pTau217 as a predictive biomarker for amyloid pathology and the broader impact of proteomic profiling in precision medicine.

This webinar will showcase how the multiplexed assay is setting a new benchmark for biomarker research, enabling high-sensitivity, low-volume detection to transform Alzheimer’s and dementia diagnostics, research and clinical applications.

Register for this webinar to gain insights into highly sensitive multiplexed assay and plasma proteomics for neurodegenerative disease diagnostics.

Register Now
Linkedin

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Linkedin

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.